arav-corresp.htm

 

 

 

November 17, 2020

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549

Attention: Margaret Schwartz

 

Re:

 

Aravive, Inc.

 

 

Registration Statement on Form S-3

 

 

File No. 333-248612

 

Ladies and Gentlemen:

 

Aravive, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-248612), be accelerated by the U.S. Securities and Exchange Commission to Friday, November 20, 2020 at 9:00 a.m., Eastern Time, or as soon as reasonably practicable thereafter.

 

The Company hereby authorizes its legal counsel, Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

 

 

 

Very truly yours,

 

 

 

 

Aravive, Inc.

 

 

 

 

By:

/s/ Vinay Shah

 

 

Name: Vinay Shah

 

 

Title: Chief Financial Officer

 

 

 

 

 

 cc:    Leslie Marlow, Esq.

         Patrick J. Egan, Esq.